STOCK TITAN

[8-K] The Bancorp Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) – Form 144 filing discloses a planned sale of 41,801 common shares through Fidelity Brokerage Services on or about 07/24/2025. The shares carry an aggregate market value of US$18.94 million, implying an estimated price of roughly US$453 per share. With 28.09 million shares outstanding, the proposed disposition equals approximately 0.15 % of total shares, a relatively small portion of the float.

No other MEDP securities were sold by the same account during the past three months, and the filer certifies the absence of undisclosed adverse information. The document does not reveal the seller’s name, relationship to the company, or whether the trade is under a Rule 10b5-1 plan, leaving limited insight into the motivation behind the sale.

Medpace Holdings, Inc. (MEDP) – Deposito del Modulo 144 rivela una vendita pianificata di 41.801 azioni ordinarie tramite Fidelity Brokerage Services intorno al 24/07/2025. Le azioni hanno un valore di mercato complessivo di 18,94 milioni di dollari USA, corrispondente a un prezzo stimato di circa 453 dollari per azione. Con 28,09 milioni di azioni in circolazione, la vendita proposta rappresenta circa il 0,15% del totale delle azioni, una quota relativamente piccola del flottante.

Negli ultimi tre mesi non sono stati venduti altri titoli MEDP dallo stesso conto, e il dichiarante certifica l'assenza di informazioni negative non divulgate. Il documento non rivela il nome del venditore, il suo rapporto con la società, né se l'operazione avviene nell'ambito di un piano Rule 10b5-1, lasciando quindi limitate informazioni sulle motivazioni della vendita.

Medpace Holdings, Inc. (MEDP) – Presentación del Formulario 144 revela una venta planificada de 41.801 acciones ordinarias a través de Fidelity Brokerage Services alrededor del 24/07/2025. Las acciones tienen un valor de mercado agregado de 18,94 millones de dólares estadounidenses, lo que implica un precio estimado de aproximadamente 453 dólares por acción. Con 28,09 millones de acciones en circulación, la disposición propuesta equivale aproximadamente al 0,15 % del total de acciones, una porción relativamente pequeña del flotante.

No se vendieron otros valores de MEDP desde la misma cuenta en los últimos tres meses, y el declarante certifica la ausencia de información adversa no divulgada. El documento no revela el nombre del vendedor, su relación con la empresa ni si la transacción está bajo un plan Rule 10b5-1, dejando limitada información sobre la motivación detrás de la venta.

Medpace Holdings, Inc. (MEDP) – Form 144 제출2025년 7월 24일경 Fidelity Brokerage Services를 통해 41,801주 보통주 매각 계획을 공개합니다. 해당 주식의 총 시장 가치는 1,894만 미국 달러로, 주당 약 453달러로 추정됩니다. 발행 주식 수가 2,809만 주인 가운데, 이번 매각은 전체 주식의 약 0.15%에 해당하는 비교적 적은 규모입니다.

지난 3개월간 동일 계좌에서 다른 MEDP 증권 매각은 없었으며, 제출자는 미공개 부정적 정보가 없음을 인증합니다. 문서에는 매도자의 이름, 회사와의 관계, 또는 Rule 10b5-1 계획에 따른 거래 여부가 공개되지 않아 매각 동기에 대한 정보는 제한적입니다.

Medpace Holdings, Inc. (MEDP) – Dépôt du formulaire 144 révèle une vente prévue de 41 801 actions ordinaires via Fidelity Brokerage Services aux alentours du 24/07/2025. Les actions représentent une valeur marchande totale de 18,94 millions de dollars US, ce qui implique un prix estimé d'environ 453 dollars par action. Avec 28,09 millions d'actions en circulation, la cession proposée équivaut à environ 0,15 % du total des actions, une part relativement faible du flottant.

Aucun autre titre MEDP n'a été vendu par le même compte au cours des trois derniers mois, et le déclarant certifie l'absence d'informations défavorables non divulguées. Le document ne révèle pas le nom du vendeur, sa relation avec la société, ni si la transaction est réalisée dans le cadre d'un plan Rule 10b5-1, offrant ainsi peu d'informations sur les motivations de la vente.

Medpace Holdings, Inc. (MEDP) – Form 144 Einreichung gibt einen geplanten Verkauf von 41.801 Stammaktien über Fidelity Brokerage Services am oder um den 24.07.2025 bekannt. Die Aktien haben einen gesamten Marktwert von 18,94 Millionen US-Dollar, was auf einen geschätzten Preis von etwa 453 US-Dollar pro Aktie hindeutet. Bei 28,09 Millionen ausstehenden Aktien entspricht die vorgeschlagene Veräußerung etwa 0,15 % der Gesamtaktien, ein relativ kleiner Anteil des Streubesitzes.

In den letzten drei Monaten wurden keine anderen MEDP-Wertpapiere vom selben Konto verkauft, und der Einreicher bestätigt das Fehlen nicht offengelegter negativer Informationen. Das Dokument nennt weder den Namen des Verkäufers noch dessen Beziehung zum Unternehmen oder ob der Handel unter einem Rule 10b5-1 Plan erfolgt, was nur begrenzte Einblicke in die Verkaufsgründe erlaubt.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: $18.9 M sale (0.15 % float) is modest; neutral-to-slightly negative signal given missing seller details.

The filing flags an insider-level disposition but the absolute and relative sizes are small, so dilution and control effects are negligible. Absence of past-90-day sales suggests no ongoing liquidation trend. However, lack of disclosure around the seller and any 10b5-1 plan limits transparency, preventing investors from evaluating whether the move is routine diversification or reflects a less favorable outlook. Until identity and context are clarified, the market impact should remain muted, but risk-averse investors may view any insider sale as a cautionary note.

Medpace Holdings, Inc. (MEDP) – Deposito del Modulo 144 rivela una vendita pianificata di 41.801 azioni ordinarie tramite Fidelity Brokerage Services intorno al 24/07/2025. Le azioni hanno un valore di mercato complessivo di 18,94 milioni di dollari USA, corrispondente a un prezzo stimato di circa 453 dollari per azione. Con 28,09 milioni di azioni in circolazione, la vendita proposta rappresenta circa il 0,15% del totale delle azioni, una quota relativamente piccola del flottante.

Negli ultimi tre mesi non sono stati venduti altri titoli MEDP dallo stesso conto, e il dichiarante certifica l'assenza di informazioni negative non divulgate. Il documento non rivela il nome del venditore, il suo rapporto con la società, né se l'operazione avviene nell'ambito di un piano Rule 10b5-1, lasciando quindi limitate informazioni sulle motivazioni della vendita.

Medpace Holdings, Inc. (MEDP) – Presentación del Formulario 144 revela una venta planificada de 41.801 acciones ordinarias a través de Fidelity Brokerage Services alrededor del 24/07/2025. Las acciones tienen un valor de mercado agregado de 18,94 millones de dólares estadounidenses, lo que implica un precio estimado de aproximadamente 453 dólares por acción. Con 28,09 millones de acciones en circulación, la disposición propuesta equivale aproximadamente al 0,15 % del total de acciones, una porción relativamente pequeña del flotante.

No se vendieron otros valores de MEDP desde la misma cuenta en los últimos tres meses, y el declarante certifica la ausencia de información adversa no divulgada. El documento no revela el nombre del vendedor, su relación con la empresa ni si la transacción está bajo un plan Rule 10b5-1, dejando limitada información sobre la motivación detrás de la venta.

Medpace Holdings, Inc. (MEDP) – Form 144 제출2025년 7월 24일경 Fidelity Brokerage Services를 통해 41,801주 보통주 매각 계획을 공개합니다. 해당 주식의 총 시장 가치는 1,894만 미국 달러로, 주당 약 453달러로 추정됩니다. 발행 주식 수가 2,809만 주인 가운데, 이번 매각은 전체 주식의 약 0.15%에 해당하는 비교적 적은 규모입니다.

지난 3개월간 동일 계좌에서 다른 MEDP 증권 매각은 없었으며, 제출자는 미공개 부정적 정보가 없음을 인증합니다. 문서에는 매도자의 이름, 회사와의 관계, 또는 Rule 10b5-1 계획에 따른 거래 여부가 공개되지 않아 매각 동기에 대한 정보는 제한적입니다.

Medpace Holdings, Inc. (MEDP) – Dépôt du formulaire 144 révèle une vente prévue de 41 801 actions ordinaires via Fidelity Brokerage Services aux alentours du 24/07/2025. Les actions représentent une valeur marchande totale de 18,94 millions de dollars US, ce qui implique un prix estimé d'environ 453 dollars par action. Avec 28,09 millions d'actions en circulation, la cession proposée équivaut à environ 0,15 % du total des actions, une part relativement faible du flottant.

Aucun autre titre MEDP n'a été vendu par le même compte au cours des trois derniers mois, et le déclarant certifie l'absence d'informations défavorables non divulguées. Le document ne révèle pas le nom du vendeur, sa relation avec la société, ni si la transaction est réalisée dans le cadre d'un plan Rule 10b5-1, offrant ainsi peu d'informations sur les motivations de la vente.

Medpace Holdings, Inc. (MEDP) – Form 144 Einreichung gibt einen geplanten Verkauf von 41.801 Stammaktien über Fidelity Brokerage Services am oder um den 24.07.2025 bekannt. Die Aktien haben einen gesamten Marktwert von 18,94 Millionen US-Dollar, was auf einen geschätzten Preis von etwa 453 US-Dollar pro Aktie hindeutet. Bei 28,09 Millionen ausstehenden Aktien entspricht die vorgeschlagene Veräußerung etwa 0,15 % der Gesamtaktien, ein relativ kleiner Anteil des Streubesitzes.

In den letzten drei Monaten wurden keine anderen MEDP-Wertpapiere vom selben Konto verkauft, und der Einreicher bestätigt das Fehlen nicht offengelegter negativer Informationen. Das Dokument nennt weder den Namen des Verkäufers noch dessen Beziehung zum Unternehmen oder ob der Handel unter einem Rule 10b5-1 Plan erfolgt, was nur begrenzte Einblicke in die Verkaufsgründe erlaubt.

false 0001295401 0001295401 2025-07-24 2025-07-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  July 24, 2025

 

The Bancorp, Inc.

(Exact name of registrant as specified in its charter)

 

Commission File Number:  000-51018

 

Delaware   23-3016517
(State or other jurisdiction of   (IRS Employer
incorporation)   Identification No.)

 

409 Silverside Road

Wilmington, DE 19809

(Address of principal executive offices, including zip code)

 

302-385-5000

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[_]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading

Symbol(s)

  Name of each exchange on which registered
Common Stock, par value $1.00 per share   TBBK   Nasdaq Global Select

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).

 

[_] Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]

 

 

 

 

 

 

 

 

Item 2.02.    Results of Operations and Financial Condition

 

On July 24, 2025, The Bancorp, Inc. (the "Company") issued a press release regarding its earnings for the three and six months ended June 30, 2025. A copy of this press release is furnished with this report as Exhibit 99.1.

 

Item 7.01.    Regulation FD Disclosure.

 

The Company hereby furnishes the information set forth in the presentation attached hereto as Exhibit 99.2, which is incorporated herein by reference. 

 

The information in this Current Report, including the exhibits hereto, are being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended. 

 

 

Item 9.01.  Financial Statements and Exhibits

 

  (d) Exhibits
       
  99.1   Press Release
  99.2    Investor Presentation 
  104   Cover Page Interactive Data File (embedded within the Inline XBRL document)
       

 

 

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date:  July 24, 2025 The Bancorp, Inc.
     
  By: /s/ Martin Egan
  Name: Martin Egan
  Title: MD, Interim Chief Financial Officer and Chief Accounting Officer
   

 

 

FAQ

How many Medpace (MEDP) shares are being sold under this Form 144?

The filing covers 41,801 common shares of Medpace Holdings, Inc.

What is the dollar value of the proposed MEDP share sale?

The aggregate market value is approximately US$18.94 million.

What percentage of Medpace’s outstanding shares does the sale represent?

It equates to about 0.15 % of the 28.09 million shares outstanding.

When is the anticipated sale date for the MEDP shares?

The approximate sale date listed is 07/24/2025.

Were any MEDP shares sold by this insider in the past three months?

No; the filing states “Nothing to Report” for prior 3-month sales.

Is the trade linked to a Rule 10b5-1 plan?

The Form 144 does not specify whether the sale is under a 10b5-1 trading plan.
Bancorp

NASDAQ:TBBK

TBBK Rankings

TBBK Latest News

TBBK Latest SEC Filings

TBBK Stock Data

3.25B
44.26M
4.06%
107.36%
12.77%
Banks - Regional
National Commercial Banks
Link
United States
WILMINGTON